UBS Group Raises Blueprint Medicines (NASDAQ:BPMC) Price Target to $129.00
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price target lifted by investment analysts at UBS Group from $88.00 to $129.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. UBS Group’s target price would indicate a potential upside of 0.90% from the stock’s […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price target lifted by investment analysts at UBS Group from $88.00 to $129.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. UBS Group’s target price would indicate a potential upside of 0.90% from the stock’s […]
